Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab

Authors

  • Hasan Cagri Yildirim Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey https://orcid.org/0000-0003-3060-377X
  • Hicran Anik Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey https://orcid.org/0009-0001-7992-4008
  • Deniz Ates Ozdemir Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Rashad Ismayilov Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey https://orcid.org/0000-0002-7093-2722
  • Arif Akyildiz Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey https://orcid.org/0000-0002-4452-2076
  • Kerim Cayiroz Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey https://orcid.org/0009-0002-1063-7948
  • Fahri Ceyhan Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Oguzalp Kavruk Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Deniz Can Guven Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
  • Ozturk Ates Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey https://orcid.org/0000-0003-0182-3933
  • Alp Usubutun Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Zafer Arik Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

DOI:

https://doi.org/10.17305/bb.2024.10255

Keywords:

Metastatic cervical cancer, squamous cell carcinoma (SCC), vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1 alpha (HIF-1 alpha), bevacizumab

Abstract

This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor (VEGF)-based therapy. A retrospective multicenter study (n = 34) explored HIF-1 alpha expression via immunohistochemistry in patients treated with platinum chemotherapy and bevacizumab. Median progression-free survival (PFS) was significantly lower in the HIF-1 alpha low score group compared to the high score group (4.9 vs 12.9 months, P = 0.014). Similarly, the median overall survival (OS) was significantly reduced in the HIF-1 alpha low score group (8.3 vs 20.4 months, P = 0.006). This study, the first of its kind, highlights the prognostic significance of HIF-1 alpha expression in metastatic cervical SCC patients treated with bevacizumab-based therapy.

Citations

Downloads

Download data is not yet available.
Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab

Downloads

Published

05-03-2024

Issue

Section

Research article

Categories

How to Cite

1.
Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab. Biomol Biomed [Internet]. 2024 Mar. 5 [cited 2024 Nov. 14];24(4):998-1003. Available from: https://bjbms.org/ojs/index.php/bjbms/article/view/10255